跳至主要内容
临床试验/NCT01672905
NCT01672905已完成不适用

Evaluation of PSA Antibody on E9802: Confirmation and Concordance

Eastern Cooperative Oncology Group0 个研究点目标入组 20 人开始时间: 2012年12月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
主要终点
PSA antibody levels are compared between baseline and follow-up at 12 weeks, as well as 24 weeks, using Wilcoxon signed-rank test

研究概览

简要总结

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in samples from patients treated for prostate cancer on trial ECOG-E9802.

详细描述

OBJECTIVES:

Primary

  • To evaluate changes in prostate-specific antigen (PSA) antibody levels over time among patients treated on ECOG-E9802.

Secondary

  • To characterize the concordance of PSA antibody assessment between the ECOG Immunology Laboratory and the NCI Immunology Laboratory.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

PSA antibody levels are compared between baseline and follow-up at 12 weeks, as well as 24 weeks, using Wilcoxon signed-rank test

时间窗: 12 weeks

次要结局

  • Concordance of PSA antibody assessment between the ECOG Immunology Laboratory and the NCI Immunology Laboratory; concordance correlation coefficient will be computed(12 Weeks)

研究者

申办方类型
Network
责任方
Sponsor

相似试验